FDA, Kaiser evaluating PROs in pancreatic cancer patients

FDA launched a study to explore patient-reported outcomes in patients with newly diagnosed pancreatic cancer. The agency's Office of Hematology and Oncology Products partnered with Kaiser Foundation Research Institute to conduct the prospective natural history study.

The research seeks to identify how PROs measure physical function during treatment and follow-up for pancreatic cancer, and how electronic health records at a large healthcare system capture those outcomes. The study will include data from Kaiser Permanente Northern California...